Kinesin spindle protein (KSP), a microtubule-associated motor protein essential for cell cycle progression, is overexpressed in many cancers and is a potential anti-tumor target. We found that inhibition of KSP by a selective inhibitor, ARRY-520, blocked cell cycle progression, leading to apoptosis in acute myeloid leukemia cell lines that express high levels of KSP. Knockdown of p53, overexpression of XIAP and mutation in caspase-8 did not significantly affect sensitivity to ARRY-520, suggesting that the response is independent of p53, XIAP and the extrinsic apoptotic pathway. Although ARRY-520 induced mitotic arrest in both HL-60 and Bcl-2-overexpressing HL-60Bcl-2 cells, cell death was blunted in HL-60Bcl-2 cells, suggesting that the apoptotic program is executed through the mitochondrial pathway. Accordingly, inhibition of Bcl-2 by ABT-737 was synergistic with ARRY-520 in HL-60Bcl-2 cells. Furthermore, ARRY-520 increased Bim protein levels prior to caspase activation in HL-60 cells. ARRY-520 significantly inhibited tumor growth of xenografts in SCID mice and inhibited AML blast but not normal colony formation, supporting a critical role for KSP in proliferation of leukemic progenitor cells. These results demonstrate that ARRY-520 potently induces cell cycle block and subsequent death in leukemic cells via the mitochondrial pathway and has the potential to eradicate AML progenitor cells.
Introduction
Microtubule-targeting agents such as taxanes, which stabilize microtubule polymers, and vinca alkaloids, which inhibit tubulin polymerization, are among the most effective drugs against a variety of cancers, 1 including breast, ovarian, and lung carcinomas and leukemias. However, their use is hindered by the toxicity arising from disruption of overall cellular microtubule dynamics not associated with cellular proliferation. Therefore, selectively targeting microtubule components should constitute a novel therapeutic strategy to limit cancer cell proliferation.
Kinesin spindle protein (KSP, Eg5), a member of the kinesinlike protein family, is a microtubule-associated motor protein that hydrolyzes ATP, causing it to move toward the plus ends of microtubules. 2, 3 KSP plays an important role in maintaining spindle dynamics and is essential for chromosome positioning, centrosome separation, the establishment of a bipolar spindle and separation of the spindle during mitosis. 4, 5 Its intrinsic biological functions suggest that KSP is an important target of anticancer therapy. Studies in mice have shown that Eg5 expression by retroviral insertion contributes to the development of mouse B-cell leukemia, 6 suggesting that Eg5 plays a role in leukemogenesis. In pancreatic carcinoma cells, the kinesinrelated protein HsEg5 has been identified as a central molecule involved in the antiproliferative action of all-trans-retinoic acid. 7 In addition, KSP was shown to be highly expressed in transformed cells in culture, but less so in primary cells. Its expression is also higher in breast, colon, lung, ovary and uterine carcinomas than in their adjacent tissues. 8 Importantly, Eg5 was recently shown to be highly expressed in blast crisis CML. 9 These findings indicate the potential importance of KSP as a target of anticancer therapy. Indeed, we observed that an Eg5 antisense oligonucleotide (ASO) was able to induce G2M cell cycle block and cell death in CML cells, independent of the cellular responses to imatinib.
As KSP functions exclusively in mitosis, KSP inhibitors have recently been developed as a new generation of anti-mitotic agents for cancer therapy, and some that have already been studied in phase 1/2 clinical trials have shown antiproliferative effects without causing significant neuropathy. [11] [12] [13] [14] [15] ARRY-520, developed by Array BioPharma, Inc., is one such agent that has shown efficient KSP inhibition and pharmacodynamic activity in animal models of solid tumors. 16, 17 However, the effectiveness of these compounds in leukemia has not been tested, and their mechanisms of action are largely unknown.
In a search for more effective and improved therapies for patients with AML, an aggressive hematological malignancy associated with high relapse rates and a generally poor prognosis with chemotherapy as the current primary treatment, we examined the effect of ARRY-520 on various acute leukemia cells. We found that inhibition of KSP effectively induced cell cycle block and the death of these cells via the mitochondrionmediated apoptotic pathway, and that ARRY-520 potently inhibited tumor growth in xenografts and the colony-forming capacity of AML blasts.
Materials and methods

Cells and cell cultures
U937, Jurkat, JurkatI9.2 18 and HL-60 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and Molm13 cells from Fujisaki Cell Center, Hayashibara Biochemical Labs, Inc. (Okayama, Japan). OCI-AML3 cells were kindly provided by Dr M Minden (Ontario Cancer Institute, Toronto, Ontario, Canada). OCI-AML3p53shRNA, p53 knockdown OCI-AML3 cells and OCI-AML3vec, the control cells, were generated as described previously. 19 XIAP-overexpressing U937 (U937XIAP) and the control (U937neo) cells were kindly provided by Dr D Kufe (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA). 20 Bcl-2-overexpressing HL-60 cells (HL-60Bcl-2) were a gift of Dr K Bhalla (Medical College of Georgia Cancer Center, Augusta, GA, USA). Fresh primary AML patient samples were acquired after informed consent following institutional guidelines. Mononuclear cells were purified by Ficoll-Hypaque (Sigma Chemical Co., St Louis, MO, USA) density-gradient centrifugation. Cells were cultured in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Treatment of cells
Exponentially growing cells (0.4 Â 10 6 /ml) were treated with ARRY-520 (Array BioPharma, Inc., Boulder, CO, USA) for up to 48 h. For combination, HL-60 and HL-60Bcl-2 cells (0.4 Â 10 6 / ml) were incubated with ARRY-520, ABT-737 or both for up to 96 h. ABT-737, a selective Bcl-2 inhibitor, 21 was synthesized at MD Anderson Cancer Center based on the published structure. DMSO was used as the control agent.
To inhibit KSP expression, 3 Â 10 6 exponentially growing HL-60 cells were transfected with 5 mg of either the KSP ASO or its control oligonucleotide (NSO) (both kindly supplied by ISIS Pharmaceuticals) using Nucleofector solution T and program K-17 following the manufacturer's instructions (Amaxa Biosystems, Cologne, Germany) and as described previously. 10 
Cell viability assay
Apoptosis was estimated by flow cytometry measurements of phosphatidyl serine 22 with the Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Indianapolis, IN, USA). Membrane integrity was simultaneously assessed by 7-amino-actinomycin D (7-AAD). To measure changes in the mitochondrial membrane potential (MMP), cells were loaded with CMXRos (300 nM) and MitoTracker Green (500 nM) (both from Invitrogen, Carlsbad, CA, USA) for 1 h at 37 1C. The loss of MMP was then assessed by measuring CMXRos retention while simultaneously adjusting for mitochondrial mass.
Cell cycle distribution
Cells were fixed with 70% ice-cold ethanol and stained with propidium iodide (PI) solution (25 mg/ml PI, 180 U/ml RNase, 0.1% Triton X-100, and 30 mg/ml polyethylene glycol in 4 mM citrate buffer, pH 7.8). The DNA content was determined using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). The cell cycle distribution was analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA).
TUNEL assay
To determine the cell cycle stage of apoptotic cells, cells were fixed in 4% formaldehyde and permeabilized with 0.1% Triton X-100. TUNEL assay was performed using the Apo-Direct Kit following the manufacturer 0 s instructions (BD Biosciences, San Jose, CA, USA).
Western blot analysis
Western blot analysis was performed as described previously. 23 
Colony-formation assay
Colony-formation assay was performed as described previously, 24 using 1 Â 10 5 mononuclear cells from the bone marrow of AML patients and cells from normal blood obtained by apheresis treated with ARRY-520, 3.3-100 nM.
Xenograft studies in SCID mice
HL-60 or MV4-11 cells growing in IMDM supplemented with 20 or 10% FBS, Glutamax and antibiotic-antimycotic were harvested when they reached approximately 10 6 per ml. Female SCID-beige mice were implanted subcutaneously in the right flank with 10 7 HL-60 or MV4-11 cells per mouse in 100 ml PBS. Twenty-one days later for HL-60-injected mice, and eighteen days later for MV4-11-injected mice, tumors were measured with a calipers and tumor volume calculated using the formula volume ¼ (length Â width 2 )/2. Mice were randomized into five or eight per group, with an average tumor volume of approximately 265 or 275 mm 3 in each group for HL-60-or MV4-11-injected mice, respectively. Treatment began on the day of randomization (day 1). Mice injected with HL-60 were dosed with vehicle or ARRY-520 in 25% PEG400/10% EtOH/ 65% saline intraperitoneally, at 27 mg/kg, on days 1, 5 and 9. Mice injected with MV4-11 were dosed with vehicle or ARRY-520, at 20 mg/kg, on days 1, 5, 9 and 53, and the surviving vehicle-treated mice were later injected with ARRY-520 on days 28, 53 and 67. Tumor volume and animal weights were measured twice a week during the course of the study.
Statistics
All experiments were performed in triplicate and results expressed as the mean ± s.e., unless otherwise stated. IC50 (the concentration inducing annexin V positivity in 50% of cells) was calculated using CalcuSyn software (Biosoft, Ferguson, MO, USA). The combination index (CI) was determined by the ChouTalalay method 25 using CalcuSyn software, and was expressed as the average±s.e. of the CI values obtained at ED50, ED75 and ED90. A CIo1 indicates a synergistic effect; CI ¼ 1 an additive effect; and CI41 an antagonistic effect.
Results
Inhibition of KSP by ARRY-520 potently induces cell death in acute leukemic cells
We first showed by western blot that KSP, the target of ARRY-520, is highly expressed in HL-60, Jurkat, OCI-AML3, U937 and Molm13 cells and in most samples of AML blasts at various levels ( Figure 1 ). We then treated these cell lines with ARRY-520 and found a decrease in cell viability with a concomitant increase in cell death in all cases. As shown in Figure 2a ARRY-520 impairs cell cycle progression and induces cell cycle block, leading to cell death To determine its effect on cell cycle, we performed cellcycle analysis in OCI-AML3 cells treated with 1 nM ARRY-520. At 24 h, a significant amount of G2M cells (24.1 versus 12.3% in DMSO control) and sub-G1 cells (26.7 versus 4.9% in DMSO control) were detected (Figure 3a) . A time-course analysis showed that cell cycle blockage was detected prior to cell death: G2M block was detectable at 6 h and more prominent at 16 and 24 h, whereas cell death was detectable at 16-24 h and more pronounced at 48 h (Figure 3b and c) . TUNEL assay further demonstrated that dead cells were primarily derived from G2M cells (Figure 4) . Similar results were obtained with U937 cells (not shown). These results suggest that KSP inhibition induces G2M cell cycle block, which leads to cell death.
ARRY-520-induced cell death is independent of p53 status, XIAP levels and activation of the extrinsic pathway
The finding that p53 wild-type OCI-AML3 and Molm13 cells are very sensitive to ARRY-520 prompted us to examine the role of p53 in ARRY-520-induced cell death. As shown in Figure 5a , ARRY-520 induced the expression of p53 in vector control OCIAML3vec cells, but not in p53 knockdown OCI-AML3p53shR-NA cells, confirming the p53 knockdown status of the cells. However, there were no apparent differences in the levels of apoptosis and cell cycle block between OCI-AML3p53shRNA cells and OCI-AML3vec cells determined by caspase-3 activation (Figure 5a ), annexin V positivity (Figure 5b ) or PI staining for DNA content (Figure 5c ).
To test whether XIAP, a potent caspase inhibitor that suppresses post-mitochondrial apoptosis, affects cell sensitivity and whether the activation of the extrinsic pathway is required for ARRY-520 action, we treated XIAP-overexpressing U937 cells (U937XIAP) and caspase-8-mutated Jurkat cells (JurkatI9.2) and their respective control cells (U937neo and Jurkat) with ARRY-520 and found that ARRY-520 had similar efficacy in U937neo and U937XIAP (Figure 6a ) and in JurkatI9.2 and Jurkat cells (Figure 6b) , regardless of the XIAP levels and caspase-8 status.
Activation of the intrinsic mitochondrial pathway is essential for cell death induced by KSP inhibition Next, we examined the importance of the mitochondriamediated intrinsic pathway to cell death induced by KSP inhibition. As shown in Figure 7a , ARRY-520 at 10 nM induced significant cell cycle block in both HL-60 and Bcl-2-overexpressing HL-60 (HL-60Bcl-2) cells at 24 h. However, cell death was observed only in HL-60 cells under this condition, as shown by changes in MMP and annexin V/7-AAD positivity. Even with higher concentrations of ARRY-520 and prolonged treatment, HL-60Bcl-2 cells were resistant to ARRY-520-induced cell death (Figure 7a ). These results not only further suggest that KSP inhibition induces cell cycle block leading to cell death, but also indicate that KSP inhibition-induced cell death is mediated via the mitochondrial pathway and that overexpression of Bcl-2 abrogated this effect. We next treated HL-60 and HL-60Bcl-2 cells with ARRY-520, the Bcl-2 inhibitor ABT-737, or both. As shown in Figure 7b , at 24 h, HL-60 cells were sensitive to both ARRY-520 and ABT-737. The combination only slightly increased the killing effect. In contrast, HL-60Bcl-2 cells were resistant to ARRY-520 or ABT-737 alone, but the combination significantly synergized their death (CI ¼ 0.011), confirming that Bcl-2 is a potent inhibitory factor of mitotic block-induced cell death. We then examined the protein levels of Bim, a BH3-only protein important in activating mitochondrial apoptotic pathway, in ARRY-520-treated HL-60 cells and found that the Bim level was increased in ARRY-520-treated HL-60 cells, and that this increase occurred before caspase-3 activation (Figure 7c ). Thus, induction of Bim by ARRY-520 provides a pro-apoptotic signal resulting in apoptosis induction. 
ARRY-520 significantly inhibits tumor growth of xenografts in SCID mice
To evaluate its effect in vivo, we treated SCID mice implanted with HL-60 cells with ARRY-520. As shown in Figure 8a , ARRY-520 greatly decreased tumor volumes and all five mice showed complete responses (CR) on day 15. The drug was well tolerated, with weight loss less than 20% over the course of the study in all animals and rapid recovery after completion of treatment. All the mice were killed and the experiment was terminated on day 26 owing to tumor sizes. It needs to be pointed out that although tumor growth was significantly inhibited during ARRY-520 treatment and became undetectable shortly after the treatment, tumors eventually outgrew, suggesting that prolonged/repeated treatment is required to achieve a better outcome. This is supported by our studies in MV4-11 xenograft, in which we initially followed the same treatment schedule. Tumors shrank and became undetectable (Figure 8b ), but started to grow back after day 39. We then retreated the mice with ARRY-520 on day 53. All eight mice were followed through day 60 and five of them achieved CR. For the vehicle control group, three mice survived until day 28 (the other five were terminated because of excessive tumor burden); they were then treated with three cycles of ARRY-520 (days 28, 53 and 67) and their tumors responded (Figure 8b ). They were followed through day 74.
Inhibition of KSP by ARRY-520 significantly diminishes the blast colony-forming potential of AML samples Inhibition of KSP by ARRY-520 in AML BZ Carter et al the effects of ARRY-520 on primary blast cells from patients with AML. We found that ARRY-520 did not significantly affect the viability of blasts from these patients (results not shown), largely because of the fact that the blasts from AML patients do not proliferate under short-term culture conditions and would therefore not be susceptible to a selective anti-mitotic agent. We then examined the effect of ARRY-520 on the clonogenicity of AML blasts and normal blood cells. We treated bone marrow samples from five AML patients (Supplementary Table 1 ) and blood cells from three normal samples obtained by apheresis with ARRY-520. As shown in Figure 9 , ARRY-520, at nM concentrations, strongly inhibited blast colony formation of bone marrow samples from AML patients (Figure 9a ), further supporting the antiproliferative role of KSP inhibition. At these concentrations, ARRY-520 did not affect the colony formation of cells from normal samples (Figure 9b ).
Discussion
This study demonstrated that the inhibition of KSP by ARRY-520 impairs cell cycle progression, which leads to cell death in leukemic cell lines via the activation of the intrinsic pathway. This effect is independent of either p53 and XIAP levels or the extrinsic pathway. ARRY-520 strongly inhibited tumor growth of HL-60 xenograft and blocked growth and regrowth of MV4-11 xenograft without apparent toxicity in SCID mice. Further, whereas the bulk of AML blasts were not responsive to ARRY-520 in vitro, the capacity to form colonies of AML progenitor cells, but not the normal blood cells, was strongly inhibited by ARRY-520, supporting the critical role of KSP in leukemia progenitor cell proliferation.
It has been suggested that defects in the p53-dependent apoptotic pathway decrease the sensitivity of cells to some antitumor agents, constituting an obstacle to chemotherapy, 26 and that an increase in p53 levels is required for maximal cell sensitivity to microtubule-targeting agents. 27, 28 In keeping with the notion that p53 expression is induced by DNA damage or DNA replication stress, we found that the inhibition of KSP by ARRY-520 increased p53 levels. However, we observed that ARRY-520-induced cell cycle block and cell death were independent of p53 status, which is supported by the finding that p53 knockdown cells were as sensitive to ARRY-520 as control cells. In addition, the effectiveness of ARRY-520 was essentially unchanged by XIAP overexpression or by lack of activation of the extrinsic pathway. The finding that caspase-8 mutation did not significantly change the effect of ARRY-520 is also in agreement with other reports suggesting that the extrinsic pathway is dispensable for apoptosis induced by microtubuletargeting agents. 29, 30 Thus, these agents are intriguing cancer therapeutics even in cells with XIAP overexpression or with a defect in p53 signaling, or in the extrinsic pathway, which is common in leukemic and other malignant cells.
Microtubule-targeting agents are known to induce mitochondrial membrane permeabilization and subsequent caspase activation by modulating Bcl-2 family proteins. [31] [32] [33] [34] KSP inhibitors are more selective microtubule-targeting agents that only affect spindle microtubules. The exact mechanisms by which these compounds induce cell death are less understood. The data present here demonstrated clearly that ARRY-520-induced cell death is mediated via the mitochondrial pathway. Cell death was significantly blunted in Bcl-2-overexpressing leukemic cells, which was overcome by Bcl-2 inhibition. Indeed, inhibition of Bcl-2 by ABT-737 synergized ARRY-520 in Bcl-2-overexpressing HL-60 cells, with a remarkable CI of 0.01 (Figure 7b) .
Time-course analysis demonstrated that the level of proapoptotic Bcl-2 protein Bim was increased by ARRY-520 before the activation of caspase-3, suggesting its causative effect on the activation of apoptosis. We observed a decrease in Bim levels in caspase-3-activated cells, which may result from its cleavage by caspase-3. The mechanism by which KSP inhibition induces Bim expression is unclear. Bim has been reported to be positively regulated by FOXO1 transcriptional factor, 35 and CDK2-dependent phosphorylation of FOXO1 has been reported to be an apoptotic response to DNA damage and replication stress independent of p53. 36 Owing to their exquisite selectivity and the potential antitumor effect, various KSP inhibitors have been developed and their mechanisms of action studied. In accordance with our findings, Tao et al. 37 reported in solid tumor cell lines that KSP-1A, a KSP inhibitor from Merck Research Lab (West Point, PA, USA), activates the mitochondrial apoptotic pathway in a p53-independent manner.
In the studies reported here, KSP inhibition by ARRY-520 exerted profound anti-proliferative and pro-apoptotic efficacy, independent of p53 status and XIAP overexpression, but dependent on Bcl-2. On the basis of these findings and the comparatively reduced toxicity, ARRY-520 and related compounds warrant further investigation as agents for treatment of leukemias and other cancers. Of note, a phase 1/2 study of ARRY-520 in patients with advanced myeloid leukemia is accruing patients at MD Anderson Cancer Center.
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Normal ( Figure 9 ARRY-520 greatly inhibits the colony formation capacity of bone marrow (BM) from patients with AML. BM samples from five AML patients (a) and blood cells from three normal samples obtained by apheresis (b) were treated with ARRY-520, and CFU was determined. CFU, colony-forming units.
